Satellite Symposia Sessions

Symposiums available to attendees at ASCP 2019 Annual Meeting

These breakfast and lunch symposiums are offered during meeting hours, the symposia listed here are not part of the ASCP Accredited Annual Meeting Program and are sponsored and managed independently by other organizations as indicated in the description.

A Pan-Cancer, Pan-Biomarker Exploration of the Opportunities to Realize the Potential of Precision Immuno-Oncology: Are Pathology Professionals Ready for the Challenge?

Wednesday, September 11 | 11:30 am - 12:30 pm (Lunch provided) | West Building, 211 A-B

This MasterClass and Practicum symposium will provide participating pathology professionals with latest evidence and practical guidance on immuno-oncology biomarker testing (PD-L1, MSI/MMR, TMB, etc.) in the era of precision cancer immunotherapy. Content areas covered will include best practices for biomarker testing and interpretation of results, and strategies for improving multidisciplinary collaboration.

CC/MOC/CMP Accredited – funded by Bristol-Myers Squibb (BMS) and AstraZeneca (AZ)

Understanding Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Evolving Molecular Insights & Diagnosis of an Aggressive Hematologic Malignancy

Thursday, September 12 | 6:30 am – 7:30 am (Breakfast provided) | West Building, 211 A-B

This session will feature a discussion about Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), an aggressive hematologic malignancy that often presents with skin lesions. The presentation will include an overview of the clinical characteristics and evolving diagnostic algorithms for BPDCN with practical scenarios and key points within individual case presentations and the importance of accurate diagnosis. Content areas include Surgical Pathology and Hematopathology.

Non-Accredited – funded by Stemline

AstraZeneca Product Showcase: Tissue Stewardship in the Age of Comprehensive Biomarker Testing in NSCLC

Thursday, September 12 | 12:45 pm - 2:15 pm (Lunch provided) | West Building, 211 A-B

This Molecular Pathology program will explore optimal practices for tumor tissue sample collection and tissue handling in NSCLC, reinforce the importance of tumor tissue sample quantity and quality for comprehensive biomarker testing and clinical decision making in patients with NSCLC, review potential pre-analytic roadblocks to quality biomarker testing and discuss strategies for avoiding these roadblocks.

Non-Accredited - funded by AstraZeneca

Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer: Why, Who, and How

Thursday, September 12 | 1:00 pm - 2:00 pm (Lunch provided) | West Building, 101 A-B

This symposium provides the perfect opportunity for learners to gain insights from both medical oncology and pathology experts on the evolving understanding of biomarkers predictive of response to ICIs and development of immune-related toxicities. Topics include:

  • • The Why and Who: Overview of Immune Checkpoint Blockade in Lung Cancer
  • • The How: Current Predictors of Response to Immune Checkpoint Inhibitors
  • • The Future: Development of New Predictive Biomarkers for Cancer Immunotherapy

CC/MOC/CMP Accredited - funded by AstraZeneca

Aptima Mycoplasma Genitalium Evaluation Study

Friday, September 13 | 6:45 am - 7:45 am (Breakfast provided) | West Building, 211 A-B

This presentation will provide an overview of Mycoplasma Genitalium, a highly prevalent yet overlooked sexually-transmitted pathogen, current diagnostic challenges, and prevalence. The session will provide a thorough review of the clinical validation study for Aptima Mycoplasma Genitalium Assay, the first FDA-cleared assay for the qualitative detection of this pathogen.

Non-Accredited – funded by Hologic, Inc.

Pathology Insights on Innovation in AML: The Rapid Emergence of Precision Diagnostics & Novel Therapy Across the Spectrum of Care

Friday, September 13 | 11:30 am - 12:30 pm (Lunch provided) | West Building, 101 A-B

This unique ‘MasterClass and Case Forum’ event will expose learners to the science that supports a modern approach to diagnosing AML (and its many subtypes) and optimizing the selection of subsequent treatment. Attendees will gain a key understanding of clinically relevant implications of recent evidence on novel therapeutics in AML, including where such evidence intersects with treatment decisions guided by molecular/pathology testing results. Content areas include Molecular Pathology, Education Best Practices for Pathologists and Laboratory Professionals, and Hematopathology.

CC/MOC/CMP Accredited – Funded by Jazz

PER

Medical Crossfire®: Optimizing Pathological Assessment in Lung Cancer: A Focus on Patients with EGFR Mutations SS Offered by Physicians’ Education Resource (PER)

Friday, September 13 | 11:30 am - 12:30 pm (Lunch provided) | West Building, 211 A-B

This Medical Crossfire® program will begin with an introductory lecture on “A Pathologic Assessment in NSCLC Cancer: a 2019 Update”, and then feature three in-depth segments with a multidisciplinary panel of oncology pathologists and medical oncologists discussing the Medical Crossfire® format to share best practices and to drive collaborative learning. These Medical Crossfire® segments will include NSCLC Presenting with Brain Metastases at Diagnosis, NSCLC with Limited Progression and Pathologic Assessment in Next-Line Treatment Decisions.

CC/MOC/CMP Accredited —funded by AstraZeneca